Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female Chinese subjects 18-45 years of age~* Females of childbearing potential must agree to be abstinent or else use one of the medically acceptable forms of contraception A female whose male partner has had a vasectomy must agree to use one additional form of medically acceptable contraception.~A male subject with female partner of child bearing potential must agree to use one additional form of medically acceptable contraception~-Be in good general health as assessed at Screening and have no clinically significant abnormal labs at Screening.~Exclusion Criteria:~* Pregnant or nursing female subjects or subjects who are trying to conceive~* Subjects with clinically significant neurologic, cardiovascular, hepatic, renal, endocrinologic, pulmonary, hematological, psychiatric, or other medical illness that would interfere with participation in this study~* Subjects with a history of ECG abnormalities~* Subjects who have cancer that has not been in complete remission for at least 5 years~* Male subjects with symptomatic prostatic hypertrophy that is clinically significant in the opinion of the Investigator~* Male subjects with a trans-urethral resection of the prostate or full resection of the prostate within 6 months prior to Screening~* Males with bladder neck obstruction or urinary retention that is clinically significant in the opinion of the Investigator~* Subjects with a diagnosis of glaucoma that in the opinion of the Investigator has not been adequately treated~* History of substance-related disorders within 1 year of Screening~* History of smoking or the use of nicotine containing products or electronic cigarettes within 3 months of Screening by self-reporting~* A positive alcohol breathalyzer or urine drug screen for drugs of abuse at the Screening Visit or at the beginning of each inpatient period~* Treatment with any prescription or non-prescription drugs (including vitamins, herbal, and dietary supplements) within 30 days~* Positivity for human immunodeficiency virus (HIV) or Hepatitis B surface antigen (HbsAg) or positive hepatitis C antibody at Screening~* Positive for Syphilis Antibody~* Subjects with any flu-like syndrome or other respiratory infections~* Recently vaccinated with an attenuated live virus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- PT010 (BGF MDI) 320/14.4/9.6 µg (Type: EXPERIMENTAL): PT010 Budesonide, Glycopyrronium and Formoterol Fumurate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg
- PT010 (BGF MDI) 160/14.4/9.6 µg (Type: EXPERIMENTAL): PT010 (BGF MDI) 160/14.4/9.6 µg
- PT003 (GFF MDI) 14.4/9.6 µg (Type: EXPERIMENTAL): PT003 (GFF MDI) 14.4/9.6 µg

Based on this trial design, predict the completion outcome and termination type (if applicable).